Clinical trials: sponsored by The Netherlands Cancer Institute
Radiation Necrosis, High Grade Glioma (III or IV)
Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality…
- Conditions
- Radiation Necrosis, High Grade Glioma (III or IV), Brain Metastasases, Radiation Toxicity
- Trial name
- BRAINS (NCT06888817)
- Testing
- Bevacizumab, Dexamethasone
- Where
- 6 sites in Netherlands
- Volunteers
- 408 people
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer Metastatic, Peritoneal Carcinomatosis
Galunisertib Combined With Capecitabine in Advanced CRC With PM
This is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of…
- Trial name
- NCT05700656
- Testing
- Galunisertib plus capecitabine
- Where
- 2 sites in Netherlands
- Volunteers
- 31 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Microsatellite-stable Colorectal Cancer
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
This Phase Ib trial studies the side effects and best dose of LB-100 when given with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer.
- Trial name
- CoLBAt (NCT06012734)
- Testing
- LB-100, Atezolizumab
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- The Netherlands Cancer Institute
Urothelial Bladder Cancer
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
This is a Phase 2 clinical intervention trial to assess efficacy of induction EVP to spare the bladder in stage T2-4aN0-1 urothelial bladder cancer (UBC), using a response-adapted approach
- Trial name
- FIDELIO (NCT07663747)
- Testing
- Enfortumab Vedotin, Pembrolizumab, Radiation
- Where
- 3 sites in Netherlands
- Volunteers
- 56 people
- Sponsor
- The Netherlands Cancer Institute
Non-Small Cell Lung Cancer
Boosting Osimertinib Blood Brain Barrier Penetration
The goal of this proof-of-concept clinical study is to determine the effect of combining osimertinib with febuxostat on cerebrospinal fluid concentrations of osimertinib in patients with epidermal growth factor receptor (EGFR)…
- Trial name
- OSIBBBOOST (NCT07485452)
- Testing
- Osimertinib & febuxostat
- Where
- 2 sites in Netherlands
- Volunteers
- 7 people
- Sponsor
- Maastricht University Medical Center
Glioblastoma
Glioblastoma Targeted Treatment Option Maximization by WGS
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates.
- Trial name
- GLOW (NCT05186064)
- Testing
- whole genome sequencing
- Where
- Netherlands
- Volunteers
- 164 people
- Sponsor
- UMC Utrecht
Cancer, Infertility
Late Effects of Cancer Therapies on Gonadal Function, Fertility, Efficiency of Fertility Preservation Procedures and Pregnancy Outcomes
In the past two decades, evidence-based knowledge on the prevalence and risk factors for fertility impairment, including infertility, following cancer and numerous cancer treatment regimens has significantly increased.
- Conditions
- Cancer, Infertility, Late Effects, Female Fertility
- Trial name
- Follow-AYA (NCT07622537)
- Volunteers
- 4,000 people
- Sponsor
- Karolinska Institutet
Breast Cancer
Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose…
- Trial name
- Subito (NCT02810743)
- Testing
- ddAC-CP-Olaparib, ddAC-mini CTC
- Where
- 11 sites in France, Netherlands
- Volunteers
- 174 people
- Sponsor
- The Netherlands Cancer Institute
Cocaine Use Disorder
Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder
In The Netherlands, each year, about 15 thousand people come into treatment because of problems with cocaine use. There is no approved medication for treatment of cocaine addiction and the psychosocial treatment patients receive…
- Trial name
- NCT05529927
- Testing
- Sustained-release Dexamphetamine
- Where
- Netherlands
- Volunteers
- 204 people
- Sponsor
- Parnassia Addiction Research Centre
Surgery, Ventilator Lung
Mechanical Ventilation in Surgical Patients
This is an investigator-initiated, international, multicenter, prospective, cross-sectional study that aims to 1) describe the incidence and types of postoperative pulmonary complications (PPCs), 2) describe patient demographics…
- Conditions
- Surgery, Ventilator Lung, Postoperative Complications
- Trial name
- MEET VENUS (NCT06296277)
- Testing
- Intraoperative mechanical ventilation for surgery
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Breast Cancer
Minimal Invasive Breast Cancer Excision Using Vacuum Assisted Biopsy Under Ultrasound Guidance
This study will assess whether it is feasible to remove small breast cancers completely using the Vacuum Assisted Biopsy (VAB) system System under Ultrasound guidance.
- Trial name
- MINIVAB (NCT04107636)
- Testing
- Vacuum assisted biopsy, conventional lumpectomy
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- Radboud University Medical Center
Circulating Tumor DNA, Recurrence
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the observational PLCRC-MEDOCC substudy.
- Conditions
- Circulating Tumor DNA, Recurrence, Colon Cancer Stage II
- Trial name
- CrEATE (NCT06434896)
- Testing
- ctDNA analysis after surgery
- Where
- 29 sites in Netherlands
- Volunteers
- 1,320 people
- Sponsor
- UMC Utrecht
Neoplasms
Personalized Live-remote Exercise Training for Cancer Survivors
Background Many people with cancer face ongoing problems from their disease and treatments, like fatigue, reduced physical fitness, feeling anxious or down, and neuropathy.
- Trial name
- LION (NCT06270628)
- Testing
- Exercise group
- Where
- Netherlands
- Volunteers
- 350 people
- Sponsor
- UMC Utrecht
Metastatic Breast Cancer
Effects of Exercise in Patients With Metastatic Breast Cancer
Currently, the effect of exercise on metastatic breast cancer has not been extensively studied, even though the benefits are evident in the curative setting.
- Trial name
- EFFECT (NCT04120298)
- Testing
- Supervised exercise
- Where
- Netherlands
- Volunteers
- 357 people
- Sponsor
- UMC Utrecht
Sarcoma
Assessing Health-related Quality of Life in Sarcoma Patients
Although the clinical effectiveness of sarcoma treatment has improved, long-lasting and cumulative treatment side-effects may often detract from the overall marginal advantage.
- Trial name
- NCT04071704
- Where
- 3 sites in Germany, Jordan
- Volunteers
- 654 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma (Skin Cancer)
NO Re-excision MelanomA - NORMA 2
This multicenter, phase III randomized controlled trial evaluates whether omitting re-excision after complete primary excision of cutaneous melanoma affects patient outcomes.
- Trial name
- NORMA-2 (NCT07530887)
- Testing
- Re-excision, No re-excision
- Where
- 21 sites in Netherlands
- Volunteers
- 1,749 people
- Sponsor
- Marieke Goodijk
Gastrointenstinal Stromal Tumor (GIST)
Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
Gastrointestinal stromal tumours (GISTs) are rare malignancies arising along the gastrointestinal tract. Tyrosine kinase inhibitors (TKIs) have substantially improved survival for patients with unresectable or metastatic GIST.
- Trial name
- NCT07522762
- Where
- Netherlands
- Volunteers
- 330 people
- Sponsor
- The Netherlands Cancer Institute
Small-cell Lung Cancer
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is needed.
- Trial name
- ACHILES (NCT03540420)
- Testing
- Atezolizumab
- Where
- 41 sites in Denmark, Lithuania and 4 more
- Volunteers
- 212 people
- Sponsor
- Norwegian University of Science and Technology
Ovarian Cancer
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
- Trial name
- OVHIPEC-2 (NCT03772028)
- Testing
- cisplatin
- Where
- 28 sites in United States, Denmark and 5 more
- Volunteers
- 538 people
- Sponsor
- The Netherlands Cancer Institute
Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
The phase III, multicenter, pragmatic PLANET trial aims to evaluate the benefit and safety of pembrolizumab as an addition to standard of care adjuvant treatment (capecitabine or olaparib) in triple negative breast cancer (TNBC)…
- Conditions
- Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer, Breast Cancer Stage II
- Trial name
- PLANET (NCT07486687)
- Testing
- Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib)
- Volunteers
- 1,000 people
- Sponsor
- The Netherlands Cancer Institute